• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current therapeutic research, clinical and experimental. >Ursolic Acid Provides Kidney Protection in Diabetic Rats
【24h】

Ursolic Acid Provides Kidney Protection in Diabetic Rats

机译：熊果酸为糖尿病大鼠提供肾脏保护

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Diabetic nephropathy (DN) is one of the most serious microvascular complications of diabetes and the leading cause of end-stage renal failure. However, the treatment of DN is still a problem in the world. Inflammatory process plays a critical role in the development of DN. Therefore, anti-inflammatory treatment of DN is worth exploring now and in the future.Objective: The study aimed to evaluate the impact of ursolic acid (UA) on renal function in streptozo-tocin-induced diabetes.Methods: Rats with streptozotocin-induced diabetes were treated with UA for 16 weeks. After 16 weeks, urine albumin excretion, serum creatinine, and blood urea nitrogen were measured. In addition, renal oxidative stress level, nuclear factor kappa-B (NF-kB) activity, P-selectin expression, and kidney histopathologic changes were evaluated.Results: Sixteen weeks following streptozotocin injection, the rats produced significant alteration in renal function and increased oxidative stress, NF-kB activity, and P-selectin expression in the kidneys. Interestingly, UA significantly prevented biochemical and histopathologic changes in the kidneys associated with diabetes. Compared with untreated diabetic rats, UA treatment lowered urine albumin excretion, renal oxidative stress level, NF-kB activity, and P-selectin expression. Moreover, UA treatment also improved renal histopathologic changes in rats with diabetes.Conclusions: UA treatment exhibited a protective effect on kidneys in diabetic rats, implying that UA could be a potential treatment for diabetic nephropathy.
机译：背景：糖尿病肾病（DN）是糖尿病最严重的微血管并发症之一，也是终末期肾衰竭的主要原因。然而，DN的治疗仍然是世界上的问题。炎症过程在DN的发展中起着至关重要的作用。因此，DN的抗炎治疗值得现在和将来进行研究。目的：本研究旨在评价熊果酸（UA）对链脲佐菌素诱发的糖尿病肾功能的影响。方法：链脲佐菌素诱发的大鼠糖尿病患者接受UA治疗16周。 16周后，测量尿白蛋白排泄，血清肌酐和血尿素氮。此外，还评估了肾脏的氧化应激水平，核因子κB（NF-kB）活性，P-选择素表达和肾脏组织病理学变化。结果：链脲佐菌素注射后十六周，大鼠肾功能发生了显着改变并增加肾脏中的氧化应激，NF-kB活性和P-选择素表达。有趣的是，UA可以显着预防与糖尿病相关的肾脏的生化和组织病理学改变。与未治疗的糖尿病大鼠相比，UA治疗可降低尿白蛋白排泄，肾氧化应激水平，NF-kB活性和P-选择素表达。此外，UA治疗还可以改善糖尿病大鼠的肾脏组织病理学变化。结论：UA治疗对糖尿病大鼠肾脏具有保护作用，这表明UA可能是糖尿病肾病的一种潜在治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号